WillItSurvive
No grouping · United States

Farlong Holding Corporation

Small reseller of traditional Chinese medicine supplements pursuing a stalled Nasdaq IPO.

Little protection left
Assessed 30 July 2026 · Evidence as of 30 July 2026
Not much stands between this business and its pressures.
On the recordSince 30 July 2026 · Checkable from 2026 · Every call on the record Checkpoint: Nasdaq IPO pricing decision or withdrawal after five S-1 amendments
The call

A tiny, loss-making TCM reseller with shrinking margins is trying to go public at a valuation many multiples above its actual sales.

Farlong buys and resells traditional Chinese medicine supplements online, generating only $838,000 in annual revenue while losing money fast. It cannot compete with massive established players like Beijing Tong Ren Tang and Yunnan Baiyao Group, which have billions in sales and deep market presence, nor can it stand out against AI-powered shopping sites that personalize offers better than Farlong's basic storefront. The company has only $1.06 million in cash but owes $3.19 million and burns roughly $2.25 million per year, so if its delayed stock offering fails or prices much lower than planned, it will likely run out of money within a year.

Why
01
AI pressure: None apparent. AI-driven personalization tools could copy Farlong's online storefront pitch, but no specific AI product is doing that yet. Could AI do the core job? Only partly.
02
Bigger players: Beijing Tong Ren Tang, Yunnan Baiyao Group, China Resources Sanjiu, China TCM Holdings. Billion-dollar TCM makers already sell competing products through wider networks Farlong cannot match. Could a giant copy it? Yes, easily.
03
What protects it. None identified: no patent, no exclusive supply, no locked distribution, just a pending IPO that keeps getting delayed and shrunk.
What would change this call
Whether Farlong's Nasdaq IPO prices, is downsized further, or is withdrawn by early 2026. Shows whether investors will fund the company at all given going-concern risk.
Next quarterly gross margin figure after 48.7% in the filing. Reveals whether margin erosion versus incumbents is continuing or stabilizing.
Cash balance reported in next filing versus the $1.06M level and $3.19M debt. Indicates whether the company can survive without emergency financing.
Key numbers
  • Net loss about $2.36M on $838K trailing revenue (2025-06-30)
  • Cash $1.06M against debt $3.19M (2025-06-30)
  • Deal size cut from $23M to $16M raise (2025-10-30)
Named risks
  • Going concern crisis: $1.06M cash against $3.19M debt and ~$2.25M annual cash burn. Severity: high
  • IPO stuck in repeated amendments since Aug 2025 with shrinking deal size, may be pulled or priced far below fantasy valuation. Severity: high
  • Collapsing gross margin from 70.6% to 48.7% across three reported periods signals eroding unit economics. Severity: high
  • Unresolved leadership identity between Jackson Kwok/Chiwen Wang and Simon Cheng as Interim CEO. Severity: medium
  • No proprietary IP, exclusive supply, or regulatory moat against 2,300+ licensed TCM manufacturers in China. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
China Traditional Chinese Medicine Holdings Co. Limitedlosing toPeer reported ~$2.18B TTM revenue vs Farlong's $838K, as of Jul 2026
Beijing Tong Ren Tanglosing toBillion-dollar TCM incumbent with no structural barrier for Farlong to compete against
Haleonlosing toInvesting ~CNY 4.47 billion to expand Tianjin manufacturing for China consumer health, per Jan 2026 report
Mitsuilosing toAcquired Eu Yan Sang (170 stores, 30 clinics) for ~SGD 800 million, per Jan 2026 report
Elix and NOOCIcontestingVC-backed U.S. DTC brands modernizing TCM-inspired supplement marketing as of Oct 2025
Questions people ask
Is Farlong Holding Corporation profitable?
No. Farlong reported a net loss of about $2.36 million on trailing twelve-month revenue of just $838,481 as of June 30, 2025, with an operating margin near negative 288% and negative free cash flow of roughly $2.25 million, per its S-1 filings.
When will Farlong Holding IPO on Nasdaq?
Unclear. Farlong filed its initial S-1 on August 29, 2025, targeting proposed ticker AFA, then filed five amendments through February 26, 2026, shrinking the deal from $23 million to $16 million. As of July 2026 it still has not priced or listed.
Is Farlong Holding a safe company to join or invest in?
Financial signals suggest high risk. As of June 30, 2025, Farlong held only $1.06 million cash against $3.19 million in debt, with gross margin falling from 70.6% to 48.7% across three reported periods and an unresolved CEO identity between Jackson Kwok and Simon Cheng.
Who is Farlong Holding's biggest competitor?
Farlong competes against vastly larger Traditional Chinese Medicine manufacturers including Beijing Tong Ren Tang, Yunnan Baiyao Group, and China Traditional Chinese Medicine Holdings Co. Limited, which reported roughly $2.18 billion in trailing revenue and a $905 million market cap as of July 21, 2026.
Could AI replace Farlong Holding's business?
Farlong's core is physical supplement manufacturing, which AI does not directly displace, but its only digital differentiator, the DirecTCM storefront, is easily replicated by AI-driven personalization tools available to any competitor. No source found evidence Farlong itself deploys AI operationally as of July 2026.
What is Farlong Holding's revenue?
Farlong reported trailing twelve-month revenue of $838,481 for the period ended June 30, 2025, up 24.7% year over year from about $770,000, according to figures compiled from its S-1 and S-1/A filings.
Timeline
  • 2026-02-26Fifth S-1/A amendment filed, IPO still not priced
  • 2026-01-13S-1/A amendment filed
  • 2025-12-29Simon Cheng appointed Interim CEO of subsidiary Longstar Healthpro
  • 2025-12-22S-1/A amendment filed
  • 2025-10-30IPO terms set at $16 million, 4,000,000 shares at $4.00
  • 2025-09-23S-1/A amendment filed, ticker AFA confirmed
  • 2025-08-29Initial S-1 filed for proposed $23 million Nasdaq IPO
  • 2024-07-10Simon Cheng's earlier offer letter with Longstar Healthpro dated
Revision history
30 July 2026
First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.
In the same band
Optimum CommunicationsWarner Bros. DiscoveryInflection AI
More companies little protection left →
Sources